Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

24,918 signal articles · 255 in last 24h · 118,691 total before filter · latest 28m ago
255last 24h
1548last 7d
260● bullish (7d)
159● bearish (7d)
205publishers
AllMacro294Earnings627M&A102Regulatory22Product13Analyst22
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Novo Nordisk looks to future proof as investors worry over pipeline
Reuters Videos14d agoneutralVIDEO
Novo Nordisk looks to future proof as investors worry over pipeline

<body><p>STORY: :: Novo Nordisk</p><p>'''Right now, the market isn't convinced that Novo Nordisk pipeline of experimental drugs is robust enough to fight against Lilly.''</p><p>:: How is Novo Nordisk future proofing as investors worry about pipeline?</p><p>:: August 5, 2026</p><p>:: Maggie Fick, European Pharma Industry Correspondent&nbsp;</p><p>''The drugmaker on Tuesday raised its full year profit and sales outlook, but investors are less focused on the numbers. They did look at the weaker than expected sales for its new Wegovy pill, and they're more focused on what the answer that the company has is to this question of the expirations of the patents for the company's key drugs. ''</p><p>'''So the name of the game now really is the medicines that Novo Nordisk is testing right now in trials. And also on Tuesday, Novo reported a trial failure for one of its next generation obesity drugs, obesity and diabetes drugs, CagriSema, and we think that's part of the reason that shares fell on these announcements.''</p><p>:: What is CEO Mike Doutsdar's response?</p><p>:: Novo Nordisk</p><p>''So Mike Doustdar acknowledged these recent trials setbacks, but he argued that they don't change the company's strategy. He says the answer is to move faster in research. He's been at the helm of the company now for a year. And he said one of the important steps he took was to combine research and development under one executive, and that that is helping that department move faster with trials. And he continues to say that failures are part of the pharmaceutical industry, that, trials are run with risks and so this is not unusual and they just have to keep moving. He said that it's important for Novo to stick to its strategy of bolt-on acquisitions to complement its own research and development.&nbsp;And he stressed that a transformational acquisition, a big merger, is not something on his agenda and that's for companies that have big problems.''</p></body>

CDW shares fall despite second-quarter earnings and revenue beat
InvestorsHub14d agoneutral
CDW shares fall despite second-quarter earnings and revenue beat

CDW Corporation (NASDAQ:CDW) reported second-quarter results that exceeded Wall Street expectations for both earnings and revenue, but shares dropped more than 8% in pre-market trading as investors focused on weaker margins and higher restructuring costs. The technology solutions provider posted adjusted earnings of $2.

Bond Yields Hold Declines After Treasury Maintains Borrowing Guidance
The Wall Street Journal14d agoneutral
Bond Yields Hold Declines After Treasury Maintains Borrowing Guidance

Treasury yields held earlier overnight declines after the Treasury Department signaled–again–that it has no plans to increase the sizes of note-and-bond auctions for “at least the next several quarters.” The Treasury’s guidance, made as part of its quarterly refunding announcement, was the same that it has made for the past 11 quarters dating back to the start of 2024.

Investing.com14d agoneutral
Jefferies downgrades Best Buy to Hold on slowing demand, memory cost concerns

Investing.com -- Jefferies downgraded Best Buy, a U.S. consumer electronics retailer to Hold from Buy, saying the market already reflects an optimistic outlook for second-quarter comparable sales while earnings upside beyond that could prove more limited amid softer consumer demand and rising cost pressures.

Could UnitedHealth Group (UNH) See Substantial Upside as Medicare Profits Recover?
Insider Monkey14d agoneutral
Could UnitedHealth Group (UNH) See Substantial Upside as Medicare Profits Recover?

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

Stablecoin Company Circle Swings to Profit
The Wall Street Journal14d agoneutral
Stablecoin Company Circle Swings to Profit

Circle Internet Group returned to profit in the second quarter, driven by steady growth in its USDC stablecoin despite a prolonged crypto bear market. The company on Wednesday reported net income of $48 million for the three months ended June 30, up from a net loss of $482 million in the same period last year. Quarterly revenue gained 7% to $701 million from $658 million in the year-ago period.